NEJM: New Hope for Lymphoma Patients! CAR-T is still in remission after 5 years of treatment

Cancer immunotherapy is a way to treat cancer by activating the immune system.
with the rapid development of tumor immunotherapy, cell therapy has attracted wide attention because of its high clinical remission rate in blood system cancer.
since 2018, cell therapy has overtaken cancer-related vaccines to achieve higher rates of remission, particularly in the global cell therapy competition for embedded antigen-treater T (CAR-T).
CAR-T is a genetically modified T-cell that modifies T-cells by importing car-coded genes into the patient's DNA, and the T-cell proliferates back into the patient's body to express CAR, thus activating the body's natural host defense mechanism and killing the target cells, thus achieving a stronger ability to locate and attack tumor cells than ordinary T-cells.
2017, the U.S. Food and Drug Administration (FDA) approved two CAR-T cell therapies, Kymriah and Yescarta, a milestone in the field of tumor immunology.
B-cell lymphoma is a solid tumor that occurs in B-cells.
include Hodgkin's lymphoma (HL) and non-Hodgkin's lymphoma (NHL).
is known for its many types, classic Hodgkin's lymphoma and nodding lymphocyte-based Hodgkin's lymphoma, which is now thought to originate from b-cell tumors.
study, published in the New England Journal of Medicine (NEJM), followed Kymriah's treatment for B-cell lymphoma patients for a long time.
showed that the first FDA-approved CAR-T treatment allowed 71 percent of patients to remain in remission after five years of treatment.
the study was conducted by researchers at the University of Pennsylvania's Abramson Cancer Center at Pennsylvania State University Medical Center.
the researchers treated Kymriah after receiving standard treatment in 24 patients with diffuse large B-cell lymphoma (DLBCL), the most common form of NHL, but the cancer returned.
results showed that 46 percent of patients received complete remission and 31 percent achieved progression-free survival after five years.
of the 14 patients with relapsed or incurable folytic lymphoma (the second most common form of disease), 71% achieved complete remission and 43% achieved progression-free survival within five years.
also assessed the durability of CAR-T cells in patients.
they found that 50 percent of patients with a remission period of more than one year did not have GENETIC modification of chised antigen receptors that expressed CD19 in their bodies after five years.
addition, the results represent the longest follow-up and publication of CAR-T cell therapies approved by the FDA to date for the treatment of recurring or refractic large B-cell lymphomas, bringing new hope to a wide range of lymphoma patients.
: Chong EA, et al. Lymphoma Program Investigators at the University of Pennsylvania. Five-Year Outcomes for Refractory B-Cell Lymphomas with CAR T-Cell Therapy. N Engl J Med. 2021 Feb 18; 384(7):673-674. doi: 10.1056/NEJMc2030164.MedSci Original Source: MedSci Original Copyright Notice: All text, images and audio and video materials on this website that state "Source: Mets Medicine" or "Source: MedSci Originals" are owned by Mets Medicine and are not authorized to be reproduced by any media, website or individual.
all reprinted articles on this website are for the purpose of transmitting more information and clearly indicate the source and author, and media or individuals who do not wish to be reproduced may contact us and we will delete them immediately.
at the same time reproduced content does not represent the position of this site.
leave a message here